Anbio Biotechnology (NasdaqGM: NNNN)
Health Care · Biotechnology · DE
$7.83
-10.41% today · -83.1% 1Y
Anbio Biotechnology (NasdaqGM: NNNN) operates in the Biotechnology industry within the Health Care sector. The company is valued at $383.61M and employs 27 people.
Over the last twelve months the share price has lost 83.1%, trading between 8.30 and 54.95.
Tweenvest scores Anbio Biotechnology across four factors: quality 72/100, value 72/100. Its strongest factor is quality.
NNNN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $383.61M
- Revenue (TTM)
- $8.65M
- P/E
- 59.61
- EPS
- 0.15
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $54.95
- 52-week low
- $8.30
- Avg volume (3M)
- —
- Shares outstanding
- 43.89M
- Employees
- 27
- Next earnings
- —
About Anbio Biotechnology
Anbio Biotechnology, established in 2021 and based in Frankfurt am Main, Germany, operates as a global supplier of in vitro diagnostics (IVD) products. The company's international footprint covers regions such as the European Union, Asia Pacific, North America, South America, and Africa. Their product range features various diagnostic solutions, including rapid antigen tests for SARS-CoV-2 (both individual and combined with influenza A/B). Anbio also develops and manufactures products leveraging advanced technologies like lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification (LAMP), chemiluminescence immunoassay (CLIA), and reverse-transcription polymerase chain reaction (RT-PCR). These offerings cater to a wide array of markets, including over-the-counter sales, point-of-care testing, and traditional laboratory settings.
- ISIN
- KYG0367B1059
- Founded
- 2021
- Listed since
- Feb 19, 2025
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $63.06B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $158.83 | +14.36% |
Figures last refreshed Aug 18, 2026.